Early Treatment with Human Albumin Solution in Continuous Renal Replacement Patients.
AIMS
To study the impact of early human albumin solution (HAS) in continuous renal replacement therapy (RRT) patients.


METHODS
Analysis of Randomized Evaluation of Normal versus Augmented Level (RENAL) RRT trial data.


RESULTS
Of 1,464 patients, 500 (34%) received early albumin. These patients had higher illness severity scores, greater use of mechanical ventilation, and 90-day mortality (51 vs. 41%; p < 0.001). However, early albumin carried similar RRT dependence risk among survivors at day 90 (4.9 vs. 5.8%; p = 0.62). On Cox proportional hazards regression, with standardized inverse probability of treatment weighting, early albumin was not associated with increased mortality (hazard ratio [HR]: 1.23, 95% CI: 0.97-1.55; p = 0.09) or recovery to RRT independence (HR: 0.92, 95% CI: 0.78-1.10; p = 0.38).


CONCLUSIONS
Early albumin was administered to one-third of RENAL trial patients and in those with greater illness severity. Early albumin was not independently associated with mortality risk or rate of recovery to RRT independence.
["O'Brien|Zachary|Z|", 'Finnis|Mark|M|', 'Gallagher|Martin|M|', 'Bellomo|Rinaldo|R|']
D058186:Acute Kidney Injury D000368:Aged D000079664:Continuous Renal Replacement Therapy D005260:Female D006801:Humans D053208:Kaplan-Meier Estimate D008297:Male D008875:Middle Aged D011446:Prospective Studies D000075462:Serum Albumin, Human D012720:Severity of Illness Index D016896:Treatment Outcome
Albumin Continuous renal replacement therapy Acute kidney injury